Clinical trial · Interventional
Significance of Cortactin Expression in Colorectal Adenocarcinomas
Enhanced Cortactin Expression is Associated With Increased Tumor Invasiveness and Nodal Metastasis in Egyptian Patients With Colorectal Adenocarcinomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal carcinoma is one of the most aggressive malignant epithelial neoplasms affecting the gastrointestinal tract. The incidence of colorectal carcinoma is obviously increasing in developing countries, where the physical inactivity and the consumption of animal fat-rich food became more evident. Colorectal tumorigenesis is a multistep process which is initiated by adenoma and is terminated by carcinoma, the latter shows variable degrees of tumor differentiation and invasiveness. During the adenoma-carcinoma process; a series of genetic mutations occur. Detection of these genetic mutations will help in the development of novel therapeutic agents, which in turn will improve patients' outcomes. Cortactin (CTTN) is a Src kinase substrate, encoded by a gene located on chromosome 11. CTTN binds to and activates Arp 2/3 and stabilizes the dynamic actin assembly after its formation. So, it become clear that CTTN is involved in the formation of the leading-edges cellular protrusions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Colon | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immunohistochemical staining | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- patients with colorectal carcinoma
- description
- patients with colorectal carcinoma will undergo colectomy. their colectomy specimens will be sectioned, tissue blocks will be prepared from tumor and adjacent normal mucosa. sections will be stained immunohistochemically by antibody against cortactin.
- interventionNames
- Genetic: immunohistochemical staining
Primary outcomes (1)
- measure
- immunohistochemical evaluation of Cortactin expression
- timeFrame
- 8 weeks
- description
- Fifty patients with colorectal adenocarcinoma will be enrolled in the study. Formalin-fixed and paraffin embedded tissue blocks will be prepared from the tumor and adjacent normal colorectal mucosa in the Pathology lab. Sections will be stained by Hematoxalin and Eosin to diagnose the tumor phenotype. Additional sections will be mounted on coated slides and stained immunohistochemically by antibodies against human Cortactin . immunohistochemical expression of Cortactin will be evaluated in both the tumor sections and adjacent normal mucosa by using Immuno-reactive score. Expression of Cortactin in tumor tissues will be statistically correlated to degree of tumor differentiation, tumor invasion and nodal metastasis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * patients with colorectal carcinomas who underwent colectomy operations. Exclusion Criteria: * specimens obtained by lower endoscopy only, patients who received pre-operative chemotherapy.
References
Publications (0)
Data not yet available